Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Casa D, Sung S, Mosquera JM, Rao R. Fine-needle aspiration biopsy of growing teratoma syndrome as a diagnostic pitfall of metastatic adenocarcinoma. Diagn Cytopathol. 2022;50(2):E71-E75.

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

Melanson SE, Zhao Z, Kumanovics A, Love T, Meng QH, Wu AH, et al. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals. Front Public Health. 2022;10:975781.

Boyraz B, Tajiri R, Alwaqfi RR, Paula AD, Ye Q, G Nielsen P, et al. Vulvar angiomyofibroblastoma is molecularly defined by recurrent MTG1-CYP2E1 fusions. Histopathology. 2022;81(6):841-846.

Kubiak JM, Hovan M, Davidson E, Douglass C, Burgos K, Walsh TJ, et al. Comparison between Perianal Swab and Stool Specimens for Detecting Colonization with Extended-Spectrum Beta-Lactamase-Producing and Fluoroquinolone-Resistant Enterobacterales. J Clin Microbiol. 2022;60(7):e0023422.

Liu C, Zhou N, Levitan D, Guzman JC, Fehniger J. Cutaneous metastasis of PD-L1 positive cervical carcinoma. Gynecol Oncol Rep. 2022;41:101003.

Aguilar RR, Shen Z-, Tyler JK. A Simple, Improved Method for Scarless Genome Editing of Budding Yeast Using CRISPR-Cas9. Methods Protoc. 2022;5(5).

Nickeleit V, Singh HK, Davis VG, Seshan SV. Classifying Polyomavirus Nephropathy: The "Banff" Initiative. Transpl Int. 2022;35:10299.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.